Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HRS-9231 in Healthy Chinese Subjects
NCT07123376Phase 1Completed
- Start
- Jun 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-9231 in Central nervous system diseases and vascular disease (5 arms). Primary endpoint: Adverse events, serious adverse events at Day 10. Started Jun 2024; status: completed.
02
Drugs
HRS-9231
03
Conditions
Central nervous system diseasesvascular disease
Beyond the preview
Go deeper on NCT07123376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123376.